Alemtuzumab, dabrafenib, obinutuzumab and trametinib have been added to the interaction checker as cancer drugs and interactions can be found for all the comedications.
- Alemtuzumab (Campath®, MabCampath®) is a monoclonal antibody and is indicated for the treatment of chronic lymphocytic B-cell leukemia.
- Dabrafenib (Tafinlar®, Rafinlar®) is a BRAF inhibitor and is indicated for the treatment of melanoma.
- Obinutuzumab (Gazvaro®, Gazyva®) is a monoclonal antibody and is indicated for the treatment of chronic lymphocytic B-cell leukemia.
- Trametinib (Mekinist®) is a MEK inhibitor and is indicated for the treatment of melanoma.
